![](/img/cover-not-exists.png)
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer
Stacy Loeb, E. Jeffrey Metter, Donghui Kan, Kimberly A. Roehl, William J. CatalonaVolume:
109
Year:
2012
Language:
english
Pages:
6
DOI:
10.1111/j.1464-410x.2011.10900.x
File:
PDF, 365 KB
english, 2012